Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Herédi-Szabó K[au]:

Search results

Items: 22

1.

Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury.

Longo DM, Woodhead JL, Walker P, Herédi-Szabó K, Mogyorósi K, Wolenski FS, Dragan YP, Mosedale M, Siler SQ, Watkins PB, Howell BA.

Toxicol Sci. 2019 Feb 1;167(2):458-467. doi: 10.1093/toxsci/kfy253.

2.

Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design.

Sáfár Z, Vaskó B, Ritchie TK, Imre G, Mogyorósi K, Erdő F, Rajnai Z, Fekete Z, Szerémy P, Muka L, Zolnerciks JK, Herédi-Szabó K, Ragueneau-Majlessi I, Krajcsi P.

Curr Drug Metab. 2016;17(5):430-55. Review.

PMID:
26728264
3.

Membrane Assays to Characterize Interaction of Drugs with ABCB1.

Fekete Z, Rajnai Z, Nagy T, Jakab KT, Kurunczi A, Gémes K, Herédi-Szabó K, Fülöp F, Tóth GK, Czerwinski M, Loewen G, Krajcsi P.

J Membr Biol. 2015 Dec;248(6):967-77. doi: 10.1007/s00232-015-9804-y. Epub 2015 Apr 30.

PMID:
25926125
4.

A P-gp vesicular transport inhibition assay - optimization and validation for drug-drug interaction testing.

Herédi-Szabó K, Palm JE, Andersson TB, Pál Á, Méhn D, Fekete Z, Beéry E, Jakab KT, Jani M, Krajcsi P.

Eur J Pharm Sci. 2013 Jul 16;49(4):773-81. doi: 10.1016/j.ejps.2013.04.032. Epub 2013 May 15.

PMID:
23684934
5.

Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.

Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, Chung SP, Herédi-Szabó K, Neuhoff S, Palm J, Balimane P, Zhang L, Jamei M, Hanna I, O'Connor M, Bednarczyk D, Forsgard M, Chu X, Funk C, Guo A, Hillgren KM, Li L, Pak AY, Perloff ES, Rajaraman G, Salphati L, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yamagata T, Lee CA.

Drug Metab Dispos. 2013 Jul;41(7):1367-74. doi: 10.1124/dmd.112.050542. Epub 2013 Apr 25.

6.

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, Brännström M, Chu X, Funk C, Guo A, Hanna I, Herédi-Szabó K, Hillgren K, Li L, Hollnack-Pusch E, Jamei M, Lin X, Mason AK, Neuhoff S, Patel A, Podila L, Plise E, Rajaraman G, Salphati L, Sands E, Taub ME, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yabut J, Yamagata T, Zhang L, Ellens H.

Drug Metab Dispos. 2013 Jul;41(7):1347-66. doi: 10.1124/dmd.112.050500. Epub 2013 Apr 25.

7.

The vesicular transport assay: validated in vitro methods to study drug-mediated inhibition of canalicular efflux transporters ABCB11/BSEP and ABCC2/MRP2.

Herédi-Szabó K, Kis E, Krajcsi P.

Curr Protoc Toxicol. 2012 Nov;Chapter 23:Unit 23.4. doi: 10.1002/0471140856.tx2304s54.

PMID:
23169269
8.

ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions.

Beéry E, Rajnai Z, Abonyi T, Makai I, Bánsághi S, Erdő F, Sziráki I, Herédi-Szabó K, Kis E, Jani M, Márki-Zay J, Tóth GK, Krajcsi P.

Drug Metab Pharmacokinet. 2012;27(3):349-53. Epub 2011 Nov 29.

9.

BSEP inhibition: in vitro screens to assess cholestatic potential of drugs.

Kis E, Ioja E, Rajnai Z, Jani M, Méhn D, Herédi-Szabó K, Krajcsi P.

Toxicol In Vitro. 2012 Dec;26(8):1294-9. doi: 10.1016/j.tiv.2011.11.002. Epub 2011 Nov 18. Review.

PMID:
22120137
10.

Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study.

Sziráki I, Erdo F, Beéry E, Molnár PM, Fazakas C, Wilhelm I, Makai I, Kis E, Herédi-Szabó K, Abonyi T, Krizbai I, Tóth GK, Krajcsi P.

J Biomol Screen. 2011 Sep;16(8):886-94. doi: 10.1177/1087057111414896. Epub 2011 Aug 10.

PMID:
21832259
11.

Comparison of 3 assay systems using a common probe substrate, calcein AM, for studying P-gp using a selected set of compounds.

Szerémy P, Pál A, Méhn D, Tóth B, Fülöp F, Krajcsi P, Herédi-Szabó K.

J Biomol Screen. 2011 Jan;16(1):112-9. doi: 10.1177/1087057110385230. Epub 2010 Nov 5.

PMID:
21057029
12.

ABCC2/Abcc2: a multispecific transporter with dominant excretory functions.

Jemnitz K, Heredi-Szabo K, Janossy J, Ioja E, Vereczkey L, Krajcsi P.

Drug Metab Rev. 2010 Aug;42(3):402-36. doi: 10.3109/03602530903491741. Review.

PMID:
20082599
13.

Potentiation of MRP2/Mrp2-mediated estradiol-17beta-glucuronide transport by drugs--a concise review.

Herédi-Szabó K, Jemnitz K, Kis E, Ioja E, Jánossy J, Vereczkey L, Krajcsi P.

Chem Biodivers. 2009 Nov;6(11):1970-4. doi: 10.1002/cbdv.200900102. Review. No abstract available.

PMID:
19937833
14.

Effect of membrane cholesterol on BSEP/Bsep activity: species specificity studies for substrates and inhibitors.

Kis E, Ioja E, Nagy T, Szente L, Herédi-Szabó K, Krajcsi P.

Drug Metab Dispos. 2009 Sep;37(9):1878-86. doi: 10.1124/dmd.108.024778. Epub 2009 Jun 11.

PMID:
19520776
15.

Multidrug resistance protein 2-mediated estradiol-17beta-D-glucuronide transport potentiation: in vitro-in vivo correlation and species specificity.

Herédi-Szabó K, Glavinas H, Kis E, Méhn D, Báthori G, Veres Z, Kóbori L, von Richter O, Jemnitz K, Krajcsi P.

Drug Metab Dispos. 2009 Apr;37(4):794-801. doi: 10.1124/dmd.108.023895. Epub 2008 Dec 31.

PMID:
19118132
16.

Mouse Bsep ATPase assay: a nonradioactive tool for assessment of the cholestatic potential of drugs.

Kis E, Rajnai Z, Ioja E, Herédi Szabó K, Nagy T, Méhn D, Krajcsi P.

J Biomol Screen. 2009 Jan;14(1):10-5. doi: 10.1177/1087057108326145. Epub 2008 Nov 21.

PMID:
19029016
17.

Utilization of membrane vesicle preparations to study drug-ABC transporter interactions.

Glavinas H, Méhn D, Jani M, Oosterhuis B, Herédi-Szabó K, Krajcsi P.

Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):721-32. doi: 10.1517/17425255.4.6.721 . Review.

PMID:
18611113
18.

Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance.

Kis E, Nagy T, Jani M, Molnár E, Jánossy J, Ujhellyi O, Német K, Herédi-Szabó K, Krajcsi P.

Ann Rheum Dis. 2009 Jul;68(7):1201-7. doi: 10.1136/ard.2007.086264. Epub 2008 Apr 8.

PMID:
18397960
19.

Characterization of 5(6)-carboxy-2,'7'-dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate for LTC4.

Heredi-Szabo K, Kis E, Molnar E, Gyorfi A, Krajcsi P.

J Biomol Screen. 2008 Apr;13(4):295-301. doi: 10.1177/1087057108316702. Epub 2008 Mar 18.

PMID:
18349419
20.
21.

Importance of the central region of lamprey gonadotropin-releasing hormone III in the inhibition of breast cancer cell growth.

Herédi-Szabó K, Lubke J, Toth G, Murphy RF, Lovas S.

Peptides. 2005 Mar;26(3):419-22.

PMID:
15652648
22.

High and low affinity receptors mediate growth effects of gastrin and gastrin-Gly on DLD-1 human colonic carcinoma cells.

Ahmed S, Budai B, Herédi-Szabó K, Farkas J, Tóth G, Murphy RF, Lovas S.

FEBS Lett. 2004 Jan 2;556(1-3):199-203.

Supplemental Content

Loading ...
Support Center